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Abstract 
Background 
People with schizophrenia experience increased rates of osteoporosis and may be at heightened risk 
of fractures. We conducted a systematic review and meta-analysis to investigate fractures among 
people with schizophrenia compared to people without mental illness.   
Method 
We systematically searched major electronic databases from inception till 10/2014.  Articles were 
included that reported the number of fractures in people with schizophrenia and a control group. 
Two independent authors conducted searches, completed methodological assessment and extracted 
data. Data was narratively synthesised and a random effects incidence rate ratio (IRR) meta-analysis 
was performed.  
Results 
Eight studies were included encompassing 48,384 people with schizophrenia (49.9 -75.2 years, 41-
100% female) and 3,945,783 controls. The pooled adjusted rate of fractures per 1000 person years 
was 5.54 (95% CI 4.92-5.57) in people with schizophrenia and 3.48 (95% CI 3.39-3.64) in control 
participants.  The comparative meta-analysis showed that people with schizophrenia experience rate 
of fractures compared to control participants (IRR 1.72, 95% CI = 1.24 to 2.39, I2=49%; n= 168,914).  
There was insufficient data to conduct a robust moderator analysis, but the narrative review 
consistently highlighted antipsychotic medication was an important risk factor for fractures.  
Conclusion 
People with schizophrenia are at significantly increased risk of fractures.  Future research is required 
to understand the mechanisms and should seek to validate fracture prediction algorithms used in 
the general population. Importantly there is a need to develop preventative strategies to improve 
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bone health and reduce fracture risk involving the wider multidisciplinary team and incorporating 
falls prevention strategies.   
Key words: schizophrenia, psychosis, fracture, osteoporosis, fragility fracture 
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Introduction 
Osteoporosis and associated fractures are a significant public health concern because of related 
mortality, morbidity, disability, and diminished quality of life 1,2.  Although osteoporosis is often 
referred to as the ‘silent disease’ it is highly clinically relevant due to the drastically increased risk of 
fractures which often occur as a consequence of the condition 1,2. People with schizophrenia 
experience poorer physical health outcomes including reduced bone mineral density 3-6, with a 
recent systematic review establishing that people with schizophrenia are two and a half times more 
likely to have osteoporosis than people of similar age and sex without mental illness 7.  
 
There are a multitude of complex reasons why people with schizophrenia may be at increased risk of 
fractures.  For instance, people with schizophrenia typically take antipsychotic and other 
psychotropic medication which is associated with antipsychotic induced hyperprolactinaemia and 
osteoporosis 5 and falls 8,9 which are a leading cause of fracture due to trauma.  Moreover, people 
with schizophrenia engage in lower levels of physical activity 10, have reduced lower limb strength 11 
and may experience high levels of pain 12 which are important risk factors for falls 13,14 and therefore 
increase the risk of fracture.  In addition, people with schizophrenia are at greatly increased risk of 
diabetes 15,16 which is a key risk factor for fractures in the general population 17.  Some vulnerability 
for falling and fractures may derive from the illness itself since children who later go on to develop 
schizophrenia are noted to have more motor coordination difficulties than their peers 18,19.  
Furthermore, alcohol use disorder is common in people with schizophrenia 6 and this may also 
increase risk of falling and subsequent fracture.  Other potential risk factors that may also increase 
the risk of fractures include increased levels of stress hormones such as cortisol 20-22.   
It is particularly important to determine if there is a relationship between schizophrenia and 
fractures as research in general medicine has consistently established increased levels of mortality 
following fractures 23. In addition, fractures in people with serious mental illnesses (SMI) such as 
schizophrenia can also lead to a deterioration of mental state 24, higher post-operative infection 
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rates, worse ambulatory rates after one year, and a risk of contralateral fractures 25. Unfortunately, 
complications are more likely to arise in this group.  A recent large study investigating 10,669,449 
lower limb fractures 26 established that patients with schizophrenia (0.6% of the sample) spent more 
time in hospital post fracture (11 days) than any other patient group, including other groups such as 
dementia where there has been an increased effort to reduce fractures. In addition, Menendez et al 
26 found that patients with schizophrenia experience significantly more adverse events following hip 
fractures including pneumonia, acute renal failure and deep venous thrombosis compared to those 
without mental illness (OR, 1.2; 95% CI, 1.2–1.3; p<0.001).   
Previously, a number of meta-analyses have reported that antipsychotic medication use is 
associated with an increased risk of fractures in older people 8,27. A selective narrative review in 
people with schizophrenia also indicated that osteoporotic fractures may have considerable adverse 
effects on general health, subjective well-being, the ability to engage in healthy lifestyle behaviors, 
and increased healthcare costs 9. However, to date, no systematic review or meta-analysis has 
specifically investigated the relationship between schizophrenia and fractures. This is warranted in 
order to provide a rigorous up-to-date risk profile and inform relevant policy in this area. Therefore, 
we conducted a systematic review and meta-analysis to investigate the association between 
schizophrenia and fractures.   
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Method 
This systematic review was conducted in accordance with the Meta-analysis of Observational Studies 
in Epidemiology guidelines 28 and reported in accordance with the PRISMA statement 29 following a 
predetermined but unpublished protocol. 
 
Inclusion and exclusion criteria 
We included observational studies (prospective, retrospective or cross-sectional) that: (a) included 
people with a diagnosis of schizophrenia according to recognised criteria (DSM V 30 or ICD 1031) 
together with a control group of people without a mental illness, and (b) reported the number of 
fractures over any period of time.  We also included observational studies that reported the number 
of people with schizophrenia in comparative studies containing groups with and without a fracture. 
If we included mixed samples (e.g. pooled sample of SMI) we attempted to extract the schizophrenia 
specific data. If this was not possible we contacted the authors up to two times over a one month 
period to obtain the schizophrenia specific data. If we received no response and the study included 
>80% with a diagnosis of schizophrenia we included the data. Due to the anticipated paucity of 
research, we collected data on any type and body site for the fracture that was confirmed through 
radiographs, medical note review or self-report. We did not place any language restrictions upon our 
searches. When we encountered studies reporting data from the same sample at different time 
points, we used the most recent data and/or the largest data set.   
 
Information sources and searches 
Two independent reviewers searched Academic Search Premier, MEDLINE, Psychology and 
Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus and Pubmed from inception 
until October 2014. We used the key words ‘schizophrenia’ or ‘schiz*’ or ‘psychosis’ and ‘fracture*’ 
or ‘osteoporosis’. In addition, the reference lists of all eligible articles and recent systematic reviews 
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on bone health in people with schizophrenia were considered 7,9.  Primary/corresponding authors of 
research groups were contacted where necessary.   
 
Study Selection 
After the removal of duplicates, two independent reviewers screened the titles and abstracts of all 
potentially eligible articles. Both authors applied the eligibility criteria, and a list of full text articles 
was developed through consensus. The two reviewers then considered the full texts of these articles 
and the final list of included articles was reached through consensus.   
 
Data Extraction 
Two authors independently extracted data in a predetermined database. The data collected from 
each article included: study design, geographical location, details of schizophrenia participants 
(mean age, % males, diagnosis method, details of medications and chronicity of illness, and 
comparison group participant characteristics (mean age, % males)).  We extracted data on fractures 
within the studies including the body site, method of acquiring the data, duration of data collection 
and details regarding the circumstances that contributed to fractures (e.g. falls, accidents).   
 
Methodological quality assessment 
Two authors completed methodological quality assessment of included articles using the Newcastle 
Ottawa Scale (NOS; 32). The NOS is utilized to assess the methodological quality of non-randomized 
trials and has acceptable validity and reliability 32. The assessment tool focuses on three main 
methodological features: (1) the selection of the groups, (2) the comparability of the groups and (3) 
the ascertainment of the outcome of interest. Studies were given a NOS score ranging from 0-9, with 
a score of 5 or greater indicative of satisfactory methodological quality.   
 
Data analysis 
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The results from the included studies were reported in a narrative synthesis and also a meta-analysis 
in accordance with the Cochrane reviewer’s handbook 33. Where possible we extracted raw data 
from the studies (or utilised data provided from authors upon request) regarding the number of 
people with and without a fracture in the schizophrenia and control groups.  We then corrected for 
years of observation and sample size (i.e. person-years of observation) to compare the incidence 
rates (IR) of fractures across studies of differing time points and report this a fracture rate per 1,000 
years of observation per study.  We pooled the data with a random effects meta-analysis calculating 
the incident rate ratio (IRR) to compare the rate of fracture between the two groups 33. In 
accordance with the Cochrane reviewers handbook 33 heterogeneity was assessed with the I2 
statistic and scores of 25%, 50% and 75% were classed as low, medium and high heterogeneity 
accordingly. We assessed publication bias with the visual inspection of a funnel plot 33 and the begg 
34 and egger 35 tests. Due to the anticipated dearth of studies and the heightened risk of obtaining a 
spurious result, we did not conduct moderator analysis with our results 33.  All analysis was 
conducted with Statsdirect and is presented with 95% confidence intervals (CI).   
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Results 
Search results and study selection 
The initial search identified 423 publications. After removal of duplicates, 367 abstracts and titles 
were screened (Figure 1). At the full text review stage, 44 articles were considered and 36 were 
subsequently excluded with reasons, leaving 8 articles that were included in the review. Details 
regarding the search results including reasons for exclusion of articles are summarised in figure 1.   
Figure 1 here 
Study and participant characteristics  
Among the 8 included studies, 6 investigated the number of fractures among people with 
schizophrenia and a control group 36-41 including 48,384 people with schizophrenia and 3,945,783 
people without mental illness. A further 2 studies reported the number of people with schizophrenia 
in a group of people with and without fractures (n=549 schizophrenia; 42,43). Of the included studies 
only 4 set out with the primary objective to investigate the relationship between schizophrenia and 
fractures 36-38,42.  The summary of the groups of studies are presented in table 1 and 2 respectively. 
The average age among the participants ranged from 49.9 years 36 to 75.2 years 38. The fracture sites 
considered varied in each study but the hip was the most commonly investigated 36-38,42,43. None of 
the included studies contained clear information on the possible causes of fractures such as falls or 
accidents.  Information regarding antipsychotic medication and other risk factors for osteoporosis 
and fractures was sparse among the included studies.   
Table 1 and 2 here 
Methodological quality  
The NOS summary score for each article is presented in tables 1 and 2.  All of the articles were of 
acceptable methodological quality with an average NOS score 6.25 (range 5-8).   
Narrative results 
Studies comparing the rate of fractures in people with schizophrenia and a control group 
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In a study among female patients with schizophrenia, Bishop et al 40 established that those with 
schizophrenia (13%) were more likely to have experienced a fracture in the past 12 months than the 
control group (0%, p<0.001). More recently, Kelly et al 41 investigated fractures over the past 12 
months among 1,898 females with psychosis and 14,985 controls without any history of mental 
illness or substance use disorder. The authors 41 established that similar proportions of people with 
psychosis (0.2%) and the control group had a fracture recorded in their medical records (0.3% 
control group). Jung et al 39 investigated the number of any fracture confirmed from radiograph 
among 229 inpatients with schizophrenia and established a higher rate among female patients 
(N=24, 25.8%) compared to the healthy controls of similar age (6.7%). The same results were evident 
among the male schizophrenia patients (N=31, 22.8%) compared to healthy male controls (4.6%).   
Sorensen et al 36 conducted a national data linkage in Danish hospital registers investigating hip 
fractures including 15,431 patients with schizophrenia and 3,807,597 general population controls.  
The authors pooled data from 3,353,771 individuals and found that after adjusting for numerous 
established risk factors for fracture (sex, age, education, early retirement pension, physical 
comorbidity, lifetime corticosteroids, lifetime alcohol-related diagnosis, antidepressants, 
anticholinergics, and benzodiazepines) that a diagnosis with schizophrenia was associated with an 
increased risk for hip fracture (IRR=1.19, 95%CI=1.08–1.31). However, this effect was non-significant 
after the adjustment of antipsychotic medication (IRR=1.00, 95%CI=0.90–1.11). Sorensen et al 36 also 
investigated the impact of several medication classes consumed in the preceding 4 months on hip 
fracture and found in the unadjusted analysis that exposure to anticholinergics, antidepressants, 
benzodiazepines, antipsychotics (both low-potency, medium potency and high potency), olanzapine 
and quetiapine were all associated with a significantly increased risk of hip fracture. More 
specifically, when the authors compared the number of antipsychotic medications in the previous 4 
months with those that had not taken any antipsychotic medication they found a dose response 
relationship of increased risk of hip fracture (IRR 1 antipsychotic=1.30 (95%CI=1.10–1.54), 2 
antipsychotics 1.68 (95%CI=1.35–2.07) and> 2 antipsychotics 1.81 (95%CI=1.28–2.54). The authors 
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also demonstrated there was a dose response relationship of increased risk of hip fracture among 
those on long term prolactin (IRR=1.16, 95%CI=1.09–1.24) and non-prolactin raising antipsychotic 
medication (IRR=1.23, 95%CI=1.15–1.32). 
 
In a large nationwide study, Tsai et al 37 investigated the number of major fractures among 30,335 
people with schizophrenia and 121,340 age and gender matched controls across a ten year period. 
The authors established that 5.5% of patients with schizophrenia had a major fracture compared to 
3.5% in the control group (p<0.001). The authors 37 established that patients with schizophrenia with 
higher psychiatric proportion of days covered (PDC= total number of medication covered days 
divided by the number of days in a certain time period) established that there was no dose response 
relationship, with an increasing PDC not indicating a higher fracture risk implying that the frequency 
of psychiatric medicine dose did not have an effect on major fracture risk.  However, the authors 
were not able to disentangle the influence of specific groups of psychotropic medication on fracture 
risk. Across the 10 year study37 period 473 people with schizophrenia (from 1673) died following a 
major fracture compared to 784 (from 4257) in the control group. The calculation of the RR from the 
raw data established that people with schizophrenia were at a 54% increased risk of mortality after a 
major fracture compared to the control group (RR=1. 54, 95%CI=1.39 - 1.70).  Lai et al 38 investigated 
hip fractures among a random sample of 445 patients with schizophrenia and 1,780 controls from 
the same cohort as Tsai et al 37. The authors found that people with schizophrenia were significantly 
more likely to experience hip fractures (IRR 1.91, 95% CI 1.49, 2.44).   
Rate of fractures per 1000 person years  
There was sufficient raw data from 5 studies to calculate the rate of fractures per 1000 person years 
37-41.  The rate of fractures per 1000 years were higher among participants with schizophrenia in 4 
studies 37-40 whilst they were slightly lower in Kelly et al 41.  Full details are presented in table 3.  It 
was possible to pool the adjusted rate of fractures from 5 studies 37-41 in each group.  This 
established that the rate of fractures was 5.54 (95% CI 4.92 to 5.57) fractures per 1000 person years 
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in those with schizophrenia and 3.48 (95% CI 3.39 to 3.64) fractures per 1000 person years in the 
control participants.   
Table 3 here 
Studies comparing the prevalence of schizophrenia in a fracture group and non-fracture group 
Bolton et al 43 investigated hip, wrist and vertebral fractures from hospital records in Canada.  The 
authors established that a diagnosis of schizophrenia is associated with fractures (OR=2.17, 95% CI 
1.75-2.69).  Howard et al 42 investigated 16,341 hip fracture cases in a UK general database study 
against 29,889 non-hip fracture cases. The authors established that people with a diagnosis of 
schizophrenia were more likely to experience a hip fracture (OR=1.37, 95% CI 1.32-2.28).  However, 
in the adjusted analysis when the authors investigated the influence of gender they found that male 
and female patients were not at increased risk of experiencing hip fractures (see table 3).   
 
Meta-analysis 
It was possible to pool data from five studies 37-41 involving 32,593 unique participants with 
schizophrenia and 138,186 control participants. This established an IRR of 1.72 (95% CI = 1.24 to 
2.39, I2=49%; n= 168,914) and is displayed in figure 2a. The funnel plot for the main analysis was 
broadly symmetrical (figure 2b) and the Begg-Mazumdar (Kendall's tau = 0.33 P = 0.46) and Egger 
bias tests (= 0.49 P = 0.44) did not indicate any publication bias.  In a subgroup analysis, we removed 
one study 41 with very low fracture rates in both groups and found an IRR of = 1.82 (95% CI = 1.33 to 
2.50, I2=47%, n schizophrenia=31,055, n controls=123,291).   
Insert figure 2 and 2b here 
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Discussion 
General findings 
To our knowledge this is the first systematic review and meta-analysis to investigate fractures in 
people with schizophrenia. Across the 8 eligible studies the results are unequivocal indicating that 
people with schizophrenia are at increased risk of fractures.  Both the results from the narrative 
review and meta-analyses suggest that the increased risk of fracture is approximately 50-100% in 
people with schizophrenia compared to people without mental illness. Clearly this is of concern, 
especially in light of the increased mortality rate among people with schizophrenia following major 
fractures 37 which may be attributed to the longer hospital stays and increased adverse events that 
people with schizophrenia experience following fractures 26.  
 
The reasons for the increased risk of fractures observed in people with schizophrenia are likely to be 
complex and multifactorial.  However, heightened levels of osteoporosis and reduced bone mass 
seen in this population 7 are key factors since osteoporosis is a primary risk factor for fractures 44,45.  
Only one study 39 reported osteoporosis in both groups and they established a considerable 
increased risk in the patient group (34.9% v 18.4%).  The results from the narrative review also 
implicate antipsychotic medication as being a key factor, which is not surprising given a previous 
meta-analysis has demonstrated an increased risk for older adults in receipt of antipsychotics 8.  In 
their large national database study, Sorensen et al 36 demonstrated a clear dose response 
relationship between the number of antipsychotics and fracture risk in the 4 months immediately 
prior to fracture. Interestingly, although antipsychotic hyperprolactinaemia has been proposed as 
one mechanism reducing bone mineral density and increasing fracture risk 3,5,46, Sorensen et al 36 
established there was a comparable increased risk of fractures for those taking prolactin raising and 
sparing medication.  However, it should be noted the effects of antipsychotics induced 
hyperprolactinaemia influence on bone mineral density will accumulate over many years 5,47 and due 
to the age of participants it is likely that many participants in both groups may have taken 1st 
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generation antipsychotics in the past for several years and so bone mineral density may have already 
been influenced in those taking prolactin sparing medication.  Other known risk factors for falls and 
fractures such as the presence of depression, polypharmacy, hypertension, diabetes and pain 13 are 
all highly prevalent among people with schizophrenia yet, although sporadically reported in the 
current literature 37 there was insufficient data to clarify the importance of these factors on actual 
fractures.   
Of the modifiable risk factors, lower limb muscle strength and balance are key predictors for falls 
and fractures in the general literature 13 and these are known to be impaired in people with 
schizophrenia 48,49.  Exercise is the most effective single intervention to prevent falls 50 and targeted 
exercise can improve lower limb strength, balance and may be integral in preventing falls and 
fractures in this patient group.  When one considers that exercise is associated with a reduction in 
depressive symptoms and improved metabolic outcomes in people with schizophrenia 51 and that 
exercise may be equally effective as pharmacological interventions to prevent cardiovascular disease 
related mortality 52, then the central role of exercise in the treatment of schizophrenia is increasing.  
Research in the general medical literature 53 has demonstrated that better cardiorespiratory fitness 
is associated with shorter hospital stay and reduced mortality following major surgery. Recent 
research 54 has demonstrated that people with schizophrenia have greatly reduced cardiorespiratory 
fitness and exercise interventions should seek to improve this. To this end, physiotherapists and 
other specialists such as exercise physiologists may have particularly pertinent roles in the MDT 
management of schizophrenia 55.  However, clearly future research is required to investigate and 
clarify this rationale.  Interestingly, Bishop et al 40 established that people with schizophrenia were 
less likely than the control group to receive osteoporosis screening and pharmacological 
interventions.  This is in line with a deficit in general preventative medical care seen in this group 
56,57.   
Limitations 
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Despite the fact this is the first review of its kind, it is important to consider a number of limitations 
which are predominantly reflected by limitations in the primary data. First, due to the paucity of 
data and lack of information it was not possible to conduct moderator or subgroup analyses with the 
results. Specifically, we could not clearly investigate the influence of increasing age, different 
medication classes, duration of antipsychotic exposure and other important risk factors for fractures 
on the pooled results.  However, this is partially appeased by the narrative results which included 
several very large age and sex matched studies adjusting for several confounders and still found an 
increased risk.  Second, most of the studies were cross-sectional or retrospective cohort studies. 
Future prospective studies are required to further understand fractures in people with 
schizophrenia. Third, there was heterogeneity in the reporting of fractures and in the skeletal sites 
considered thus precluding evaluation of site-specific fracture risk across the studies.   
 
Future research 
There are many research questions of relevance to the clinical care of people with schizophrenia 
that need addressing as a priority. First, there is a need to better understand the reasons why people 
with schizophrenia are more likely to experience fractures and in particular investigate the 
contributing mechanisms, with a view to developing prevention plans.  Also, research investigating 
the care of people with schizophrenia in general hospitals following fracture is warranted to 
investigate: (a) how they can be rehabilitated in the best manner and avoid prolonged stays in 
hospital and (b) why they appear more susceptible to adverse events in the hospital but also are at 
increased risk of mortality thereafter 37 
In most of the studies we reviewed, the outcome was a fracture in any part of the skeleton and the 
circumstances in which the fracture incurred were not reported.  Clearly, there is an urgent need to 
understand this in greater detail in order to prevent fractures in this group.  There is a need for 
future prospective studies with specific outcome definitions, based on the site and the 
circumstances around the fracture to elucidate the potential mechanisms for the increased fracture 
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risk observed in people with schizophrenia.  It is highly likely that heightened levels of osteoporosis 
and osteopenia reported in people with schizophrenia 7 increase the risk for fractures.  
Investigations of mobility limitations and falls risk in people with schizophrenia should be considered 
since deficits in these areas are primary causes of falls and fractures in the general population 44,45.  
Future research could also consider the prospective investigation of falls to see if this is increased in 
people with schizophrenia compared to the general population.   
Finally, our results show the importance of including fracture outcomes in prospective studies that 
provide individual patient level data in order to establish the attributable risk of schizophrenia on 
fracture, as well as the contribution of specific risk factors, including age, gender, race, weight, 
smoking, physical activity behavior (e.g. complying with health recommendations or not) and 
psychotropic medication use (e.g. use of long term prolactin raising medication or not, the use of 
benzodiazepines or not, etc.). Next to this, validation of fracture prediction algorithms used in the 
general population, such as FRAX 58 for people with schizophrenia might be an important area of 
future research to identify those most at risk of fracture. 
 
Conclusion 
Our systematic review and meta-analysis has demonstrated that people with schizophrenia are at 
increased risk of developing fractures. The exact reasons for this are not yet clear but antipsychotic 
medications are likely to contribute.  Limitations in the primary data did not enable us to elucidate 
the underlying contributors and causes of fractures and there is a need for future prospective 
research to better understand this. In addition, in light of the concerns regarding increased 
morbidity and mortality among people with schizophrenia experiencing a fracture, there is a need to 
develop preventative interventions to stop fractures occurring and this should include the wider 
multidisciplinary team.  
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Figure 1. PRISMA 2009 flow diagram for search strategy 
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Figure 2a Forest plot for the main meta-analysis 
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Figure 2b funnel plot for the main analysis  
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Table 1 – summary of included studies comparing the prevalence of fractures among people with schizophrenia compared to a control group 
Study Location and 
design 
Schizophrenia 
Diagnosis 
Schizophrenia 
Participants  
Control participants Fracture site and 
ascertainment 
NOS 
score 
Bishop et 
al 2004 
US, 
retrospective 
study 
DSMI IV N=46 
100% female 
61.1 years 
 
N=46 
100% female 
61.0 years 
Fracture in past 12 
months 
 
Medical records 
5 
Kelly et al 
2011 
US, 
retrospective 
cohort 
ICD 9  N=1898 schizophrenia 
(psychosis) 
100% female 
56 years 
N=14,985 healthy 
controls free from 
mental illness and 
substance use disorder 
100% female 
57 years 
Any fracture in past 
12 months 
 
Medical records 
6 
Jung et al 
2011 
Republic of 
Korea, cross 
sectional 
DSM IV N=229 inpatients 
40.6% female  
Mean duration illness 
142.6±79.2 months 
N=93 female, 59.1 
years 
91.4% FGA % 8.6% 
SGA 
N=136 male, 58.2 
years 
121 (89.0%) FGA and 
SGA 15 (11.0%) 
34.9% osteoporosis 
N=125 healthy controls 
48% female 
N=60 female, 58.2 years 
N=65 males, 59.0 years 
18.4% osteoporosis 
(p<0.01) 
 
Any fracture across 
lifetime 
 
Medical records 
7 
Sorensen 
et al 2013 
Denmark, 
Cohort study 
ICD 8 and ICD 
10 
N= 15,431 
41% female 
49.9 years 
N= 3,807,597 
56.9% female 
46.9 years 
Hip fracture 
Medical records 
8 
Lai et al Taiwan, cross ICD 9  N=445 N= 1780 Hip fracture 5 
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2013 sectional 52.8% female 
75.2 years 
52.8% female 
74.2 years 
 
Medical records 
Tsai et al 
2014 
Taiwan, 
prospective 
cohort 
ICD 9 N= 30,335 
51.13% female 
51.11 years 
N= 121,340 
51.13% female 
51.11 years 
Age and gender 
matched no mental 
illness  
Major fracture 
(vertebra, hip, 
humerus, forearm, 
wrist) 
 
Medical records 
8 
Key = FGA=first generation antipsychotic medication, SGA = second generation antipsychotic medication 
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Table 2 – Summary of included studies investigating the prevalence of schizophrenia in comparative studies of those with and without a fracture  
Study Location and 
design 
Schizophrenia 
Diagnosis 
Schizophrenia 
Participants with 
fracture  
Schizophrenia 
participants without 
fracture 
Fracture site and 
ascertainment 
NOS 
score 
Howard et 
al 2007 
UK, 
retrospective 
cohort 
GP records 
ICD 9 
N=100 hip fracture 
cases with 
schizophrenia (0.61% 
of all cases) 
N=110 people with 
schizophrenia non-hip 
fracture cases (0.37% of 
all non-fracture cases) 
Hip fracture 
Medical records 
6 
Bolton et 
al 2008 
Canada, 
retrospective 
cohort 
ICD 9 N= 142 fracture cases 
with schizophrenia 
(0.9% of all fracture 
cases) 
No demographic data  
All> 50 years 
N=197 people with 
schizophrenia did not 
have a fracture (0.4% of 
all non-fracture cases) 
All > 50 years 
 
Hip, wrist vertebral 
 
Medical records 
5 
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Table 3 – Results of included studies 
Study Type of fracture Results 
Sorensen et al 
2013 
Hip fracture Diagnosis of schizophrenia IRR 1.19 (95% CI 1.08–1.31) a 
 
Diagnosis of schizophrenia & adjusted for AP IRR 1.00 (95% CI 0.90–1.11) a 
Medications taken in past 4 months prior to hip fracture 
Anticholinergics IRR 1.46 (95% CI 1.26–1.70) b 
Antidepressants IRR 1.29 (95% CI 1.09–1.54) b 
Benzodiazepines IRR 1.34 (95% CI 1.14–1.58) b 
Antipsychotics IRR 1.42 (95% CI 1.21–1.65) b 
Number of antipsychotics taken: 
1 IRR 1.30 (95% CI 1.10–1.54) b 
2 IRR 1.68 (95% CI 1.35–2.07) b 
>2 IRR 1.81 (95% 1.28–2.54) b 
 
Long term prolactin raising antipsychotic medication  
(IRR 1.16 95% CI 1.09–1.24) 
Long term non prolactin raising antipsychotic medication  
(IRR 1.23 95% CI 1.15–1.32). 
Bishop et al 
2004 
Fracture in past 
12 months 
Schizophrenia participants 130.43 (95% CI 47.86-283.90) fractures per 1000 person years 
Control participants 21.73 (95% CI 0.55-121.122) fractures per 1000 person years. 
 
IRR 6.00 (95% 0.72-275.98) calculated from raw data 
 
Howard et al 
2007 
Hip fracture Diagnosis of schizophrenia 
OR 1.37 (95% CI 1.32-2.28) unadjusted univariate  
Adjusted analysis: 
Female diagnosis with schizophrenia OR 1.01 (95% CI 0.72-1.40) 
Male diagnosis with schizophrenia OR 1.61 (95% CI 0.81-3.19) 
Bolton et al 
2008 
Hip, wrist, 
vertebral 
Diagnosis schizophrenia 
OR 2.17 (95% CI 1.75-2.69) 
Jung et al 2011 Lifetime Male participants with schizophrenia 3.86 (95% CI 2.62-5.48) fractures per 1000 person 
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fracture years. 
Female participants with schizophrenia 4.10 (95% 2.62-6.10) fractures per 1000 person 
years 
 
Male control participants 0.782(95% CI 0.160-2.28) fractures per 1000 person years. 
Female control participants 1.12 (95% 0.30-2.89) fractures per 1000 person years.  
 
IRR 4.93 (95% 1.54-5.24) male participants 
IRR 3.63 (95% CI 1.24-14.40) female participants 
Calculated from raw data.   
Kelly et al 2011 Fracture in past 
12 months 
Schizophrenia participants 2.10(95% CI 0.57-5.39) fractures per 1000 person years.  
Control participants 2.95 (95% 2.14 3.96) fractures per 1000 person years 
 
IRR calculated from raw data 
0.71 (95% 0.18- 1.95) 
 
Lai et al 2013 Hip fracture Schizophrenia participants 9.43 (95% CI 6.80-12.75) fractures per 1000 person years. 
Control participants 6.34 (95% CI 5.23-7.63) fractures per 1000 person years 
IRR for hip fracture among people with schizophrenia v control group 
IRR 1.91 (95% CI 1.49, 2.44) 
IRR calculated from raw data 
1.49 (95% CI 1.01-2.03) 
 
Tsai et al 2014 Major fracture 
 
Hip fracture 
Schizophrenia participants 5.52 (95% CI 5.26-5.79) major fractures per 1000 person years. 
Control participants 3.50 (95% CI 3.40-3.61) major fractures per 1000 person years 
 
Schizophrenia participants 2.66 (95% CI 2.47-2.85) hip fractures per 1000 person years. 
Control participants 1.02 (95% CI 0.96-1.07) hip fractures per 1000 years. 
 
IRR major fracture 1.57 (95% CI 1.48-1.66) from raw data 
 
IRR hip fracture 2.60 (95% CI 2.38-2.85) from raw data 
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Hazard ratio c for osteoporotic fracture investigating psychiatric proportion of days covered 
(PDC) an indicator of the intensity of drug exposure in patients with schizophrenia 
PDC = 0                  HR 1.192 (95% CI 0.946–1.502) 
0 PDC ≦ 0.1          HR 1.190 (95% CI 0.968–1.464) 
0.1PDC ≦ 0.2        HR 1.373 (95% CI 1.059–1.782) 
0.2 PDC ≦ 0.3       HR 1.829 (95% CI 1.448–2.310) 
0.3 PDC ≦ 0.4       HR 1.829 (95% CI 1.448–2.310) 
0.4 PDC ≦ 0.5       HR 1.352 (95% CI 1.074–1.702) 
0.5 PDC ≦ 0.6       HR 1.695 (95% CI 1.388–2.071) 
0.6 PDC ≦ 0.7       HR 1.898 (95% CI 1.591–2.265) 
0.7 PDC ≦ 0.8       HR 1.563 (95% CI 1.298–1.883) 
0.8 PDC ≦ 0.9       HR 1.500 (95% CI 1.255–1.792) 
0.9 b PDC ≦ 1       HR 1.840 (95% CI 1.649–2.053) 
Key a (Sorensen et al 2013) adjusted for sex, age, education, early retirement  pension, CPDS, lifetime corticosteroids, lifetime alcohol-related diagnosis, 
antidepressants, anticholinergics, and benzodiazepines b (Sorensen et al 2013) Adjusted for sex, age at diagnosis, alcohol misuse and somatic score. c (Tsai et 
al 2014) adjusted for age, gender, osteoporotic fracture-related illnesses, level of urbanization, and socioeconomic status 
 
